Table 1. Patients’ characteristics.
| Parameters | N = 47 (%) |
|---|---|
| Gender | |
| Male | 35 (74.5) |
| Female | 12 (25.5) |
| Age | |
| > 30 | 15 (29.8) |
| ≤ 30 | 32 (70.2) |
| ECOG PS score | |
| ≥ 2 | 11 (23.4) |
| < 2 | 36 (76.6) |
| B symptoms | |
| Yes | 19 (40.4) |
| No | 28 (59.6) |
| Stage | |
| I–II | 7 (14.9) |
| III–IV | 40 (85.1) |
| Bone marrow infiltration | |
| Yes | 25 (53.2) |
| No | 22 (46.8) |
| LDH level | |
| Elevated | 16 (34.0) |
| Normal | 31 (66.0) |
| Mediastinal mass | |
| Yes | 42 (89.4) |
| No | 5 (10.6) |
| Chemotherapy regimens | |
| ECOG 2993 | 5 (10.6) |
| BFM-90 | 27 (57.4) |
| HyperCVAD/MA | 12 (25.5) |
| unspecified | 3 (6.5) |
| Interim PET-CT | |
| Positive | 19 (40.4) |
| Negative | 28 (59.6) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; HyperCVAD/MA, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine therapy.